Contact Lenses
CooperVision Completes Enrolment for World’s Largest Myopia Control Clinical Study
CooperVision Completes Enrolment for World’s Largest Myopia Control Clinical Study
Global Studies Across the US and China Will Generate Real-World Evidence to Advance, Expand, and Strengthen the Myopia Management Category
CooperVision today announced the complete enrolment of its global MiSight® 1 day post-approval clinical studies (PAS) in the United States and China, a milestone in real-world evidence generation for paediatric myopia control. Together with the 7-year clinical trial of ActivControl® Technology, which represent the longest running soft contact lens study amongst children,* including both randomised controlled efficacy trials and large-scale safety registries.1
The combined PAS programmes span more than 100 clinical sites and include over 3,000 children Data will supplement already extensive MiSight® 1 day clinical studies, which have been widely published and cited in the ophthalmology and optometry communities.
The announcement coincides with 2026 Myopia Awareness Week (May 18 – 24), reinforcing the company’s ongoing commitment to advancing the science and understanding of paediatric myopia, a condition expected to affect nearly half of the global population by 2050.2
“Completing enrolment is a crucial step, allowing us to start analysing data that will further illustrate how MiSight® 1 day performs in real-world settings over multiple years” said Kathryn Richdale, OD, PhD, Director of Post-Market Clinical Affairs, CooperVision. “The findings will further strengthen the existing evidence supporting MiSight® 1 day, helping eye care professionals continue to make informed myopia management decisions and reinforcing long‑term confidence for families.”
Participants in the multi-year studies represent populations across the US and China, providing insights applicable to children worldwide. Final data are expected on a rolling basis between 2027 and 2030.
To learn more about CooperVision’s myopia management research journey, visit www.coopervision.com.
